What Greater Pharma does

Greater Pharma is a Bangkok-based biotechnology company developing probiotic-based therapeutics for chronic kidney disease (CKD). Its core product is Lactobacillus rhamnosus L34, a native probiotic strain developed through a research collaboration with Chulalongkorn University that reduces uremic toxins and inflammation in CKD patients. The strain has been tested in animal models and initial human trials, where it demonstrated significant reductions in toxins and cytokines, and is now being advanced into a Thai-made dietary supplement targeting individuals with limited treatment options outside of dialysis.

The company's technology is biological rather than digital: a proprietary probiotic strain validated through university-conducted preclinical and early clinical work, with the differentiation framed as domain specialization in CKD rather than platform-level infrastructure. Commercial positioning emphasizes the native, Thai-developed nature of the strain and its potential route toward medical-use regulatory approvals beyond the supplement category. The IP is anchored in a single asset (L34), and operational scale signals — headcount, distribution partners, and manufacturing partnerships — are not disclosed in the source material.

Greater Pharma is a privately held pre-commercial company; no revenue, pricing, or funding figures are disclosed. Its business model centers on eventual dietary supplement sales, with distribution channels unspecified and an initial commercial footprint focused on Thailand and Southeast Asia. Customer segmentation is highly vertical, oriented around CKD patients and the nephrology-adjacent care pathway rather than a broad wellness consumer base.

Name

Greater Pharma

Website

https://greaterpharma.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Greater Pharma is a Bangkok-based biotechnology company developing Lactobacillus rhamnosus L34, a native probiotic strain that reduces uremic toxins and inflammation in chronic kidney disease patients, currently advancing the product as a Thai-made dietary supplement.

Ownership category

akta.pro rank

Product category

Probiotic Dietary Supplements

NAICS

Food Manufacturing (311)

SIC

Food And Kindred Products (2000)

akta.pro primary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

Keywords

• Probiotic dietary supplements
• Chronic kidney disease therapy
• Native probiotic strains
• Uremic toxin reduction
• Biotechnology supplements

Headquarters

HQ city

Bangkok

HQ country

Thailand

HQ region

Asia

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel

Core offering

Greater Pharma is developing probiotic-based dietary supplements, with its core product being Lactobacillus rhamnosus L34, a native probiotic strain developed in collaboration with Chulalongkorn University that reduces uremic toxins and inflammation in chronic kidney disease (CKD) patients. The strain has been tested in animal models and initial human trials, and is being developed into a Thai-made dietary supplement for CKD management.

Product overview

Greater Pharma is developing probiotic-based dietary supplements. The company's core product is Lactobacillus rhamnosus L34, a native probiotic strain that reduces uremic toxins and inflammation in patients with chronic kidney disease. This probiotic has been tested in animal models and initial human trials, demonstrating significant reductions in toxins and cytokines, and is currently being developed into a Thai-made dietary supplement.

Differentiator

Problem solved

Functional benefit

Products and services

• Lactobacillus rhamnosus L34 A native probiotic strain developed by researchers at Chulalongkorn University that reduces uremic toxins and inflammation in patients with chronic kidney disease (CKD). The probiotic has been tested in animal models and initial human trials, showing significant reductions in toxins and cytokines, and is being developed into a Thai-made dietary supplement for CKD patients.

Quantifiable outcome

• Significant reductions in uremic toxins and cytokines demonstrated in animal models and initial human trials

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Chulalongkorn UniversitycoreStrategic or Co-development PartnerResearch collaboration with Chulalongkorn University researchers who developed the Lactobacillus rhamnosus L34 probiotic strain. The university conducted animal models and initial human trials demonstrating the probiotic's effectiveness in reducing uremic toxins and inflammation in CKD patients.

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• GanedenBC30 (Kerry Group): Probiotic ingredient brand (now part of Kerry) that licenses a proprietary Bacillus coagulans strain into supplements and functional foods — comparable as a proprietary-strain probiotic ingredient licensor with branded positioning.
• Chr. Hansen (now Novonesis): Global leader in microbial and fermentation cultures, including a major probiotic strain business serving supplement, dairy, and infant nutrition customers — comparable as an upstream probiotic strain supplier and broad incumbent in the same category.
• Yakult Honsha: Japanese incumbent that built a global brand around a single Lactobacillus casei Shirota strain with clinical research behind it — comparable as an evidence-based, single-strain probiotic product company with global reach.

Direct peers

• Winclove Probiotics: Dutch probiotic formulation company that develops multi-strain and single-strain probiotic formulations for specific health indications — comparable as a small/mid-sized specialist turning proprietary probiotic strains into clinically-positioned products.
• Probi AB: Swedish probiotic company that develops, patents, and commercializes proprietary probiotic strains with documented clinical effects — similar business model of developing proprietary strains and licensing into supplements, foods, and clinical nutrition.
• Kibow Biotech: US-based biotech commercializing Renadyl, a probiotic formulation specifically developed to reduce uremic toxins in CKD patients — directly comparable in indication, mechanism, and product format to Greater Pharma's L34.
• BioGaia: Sweden-based probiotic specialist that develops and commercializes proprietary Lactobacillus and Bifidobacterium strains for clinically-validated health indications; comparable as a strain-development company using specific probiotic strains with health claims.

Emerging players

• Morinaga Milk Industry: Japanese dairy and ingredient company developing proprietary probiotic strains (e.g. Bifidobacterium longum BB536) for clinical and functional food use — comparable as an Asian-headquartered probiotic strain developer focused on clinically-substantiated products.
• Custom Probiotics: US-based niche manufacturer of custom single-strain and multi-strain probiotic formulations for clinical and consumer use — comparable as a small specialist that turns single proprietary strains into clinically-positioned supplements.

Regional players

• Dutch Mill (Thailand): Leading Thai dairy and probiotic beverage company with established probiotic yogurt and cultured drink brands — comparable as a Thailand-based company commercializing probiotic products into the same Southeast Asian consumer and channel environment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/GreaterPharmaGroup
• LinkedInlinkedin.com/company/greater-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greater Pharma